O’Sullivan J, Carroll D, Cao Y, Salicru A, Bochner B (2018) Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells. J Allergy Clin Immunol 141:1774-1785.e1777. doi: 10.1016/j.jaci.2017.06.028
Summary: Therapeutic payloads can be targeted selectively to eosinophils and malignant mast cells by exploiting this Siglec-8 endocytic pathway.
Usage: Eosinophil cell death was assessed with 2C4 mAb or isotype control (both at 2.5 μg/mL).
Related Products: Custom Conjugates